Becton, Dickinson and Company’s Quarterly Earnings Preview: What You Need to Know

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. The Franklin Lakes, New Jersey-based company operates through BD Medical, BD Life Sciences, and BD Interventional segments.

The medical technology company is expected to release its Q2 2025 earnings before the market opens on Thursday, May 1. Ahead of this event, analysts expect BDX to post adjusted earnings of $3.28 per share, reflecting a growth of 3.5% from $3.17 per share reported in the same quarter last year. In addition, the company has surpassed Wall Street's bottom-line estimates in the past four quarters.